title: Advanced stage nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents: clinical characteristics and treatment outcome - a report from the SFCE & CCLG groups.
abstract: Advanced stage nodular lymphocyte predominant Hodgkin lymphoma (nLPHL) is extremely rare in children and as a consequence, optimal treatment for this group of patients has not been established. Here we retrospectively evaluated the treatments and treatment outcomes of 41 of our patients from the UK and France with advanced stage nLPHL. Most patients received chemotherapy, some with the addition of the anti CD20 antibody rituximab or radiotherapy. Chemotherapy regimens were diverse and followed either classical Hodgkin lymphoma or B non-Hodgkin lymphoma protocols. All 41 patients achieved a complete remission with first line treatment and 40 patients are alive and well in remission. Eight patients subsequently relapsed and 1 patient died of secondary cancer (9 progression-free survival events). The median time to progression for those who progressed was 21 months (5·9-73·8). The median time since last diagnosis is 87·3 months (8·44-179·20). Thirty-six (90%), 30 (75%) and 27 (68%) patients have been in remission for more than 12, 24 and 36 months, respectively. Overall, the use of rituximab combined with multi-agent chemotherapy as first line treatment seems to be a reasonable therapeutic option.
authors.affiliation: Department of Paediatric and Adolescent Oncology, University College London Hospitals NHS Foundation Trust, London, UK.
authors.forename: Ananth G
authors.initials: AG
authors.lastname: Shankar
authors.affiliation: CHU Reims, Reims, France.
authors.forename: Gaelle
authors.initials: G
authors.lastname: Roques
authors.affiliation: Cancer Research UK & UCL Cancer Trials Centre, University College London, London, UK.
authors.forename: Amy A
authors.initials: AA
authors.lastname: Kirkwood
authors.affiliation: CHRU Lille, Lille, France.
authors.forename: Anne
authors.initials: A
authors.lastname: Lambilliotte
authors.affiliation: Department of Paediatric and Adolescent Oncology, University College London Hospitals NHS Foundation Trust, London, UK.
authors.forename: Katja
authors.initials: K
authors.lastname: Freund
authors.affiliation: AP-HP, Robert Debré Hospital, Paris, France.
authors.forename: Thierry
authors.initials: T
authors.lastname: Leblanc
authors.affiliation: Cancer Research UK Clinical Trials Unit, School of Cancer Sciences, University of Birmingham, Birmingham, UK.
authors.forename: Janis
authors.initials: J
authors.lastname: Hayward
authors.affiliation: Gustave Roussy, Villejuif, France.
authors.forename: Samuel
authors.initials: S
authors.lastname: Abbou
authors.affiliation: Department of Cellular Pathology, University College London Hospitals NHS Foundation Trust, London, UK.
authors.forename: Alan D
authors.initials: AD
authors.lastname: Ramsay
authors.affiliation: CHU Nancy, Nancy, France.
authors.forename: Claudine
authors.initials: C
authors.lastname: Schmitt
authors.affiliation: CHU Reims, Reims, France.
authors.forename: Stephanie
authors.initials: S
authors.lastname: Gorde-Grosjean
authors.affiliation: Insititut Curie, Paris, France.
authors.forename: Hélène
authors.initials: H
authors.lastname: Pacquement
authors.affiliation: CHU Montpellier, Montpellier, France.
authors.forename: Stephanie
authors.initials: S
authors.lastname: Haouy
authors.affiliation: Service d'hématologie et d'oncologie pédiatrique, Hopital A, Trousseau, 75571 APHP/UPMC Univ Paris 06, Paris, France.
authors.forename: Sabah
authors.initials: S
authors.lastname: Boudjemaa
authors.affiliation: CHU de Bordeaux, Bordeaux, France.
authors.forename: Nathalie
authors.initials: N
authors.lastname: Aladjidi
authors.affiliation: Paediatric Haematology/Oncology Unit, Children's Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
authors.forename: Georgina W
authors.initials: GW
authors.lastname: Hall
authors.affiliation: Service d'hématologie et d'oncologie pédiatrique, Hopital A, Trousseau, 75571 APHP/UPMC Univ Paris 06, Paris, France.
authors.forename: Judith
authors.initials: J
authors.lastname: Landman-Parker
mesh_terms: D000293:Adolescent; D001706:Biopsy; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy / Q000009:adverse effects / Q000379:methods; D005260:Female; D006689:Hodgkin Disease / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy*; D006801:Humans; D008297:Male; D064847:Multimodal Imaging; D009367:Neoplasm Staging; D012008:Recurrence; D019233:Retreatment; D016896:Treatment Outcome
keywords: advanced stage; chemotherapy; children and adolescents; nodular lymphocyte predominant Hodgkin lymphoma; rituximab